Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term follow-up of mTOR inhibition for Erdheim-Chester disease

16 Apr 2020

Abstract excerpt

Two articles this week focus on Erdheim-Chester disease (ECD), a rare histiocytosis that mainly affects adults. Clonal somatic mutations primarily involving proteins in the BRAF and MPAK pathways have established ECD as a myeloid neoplasm, with targeted therapies now available for patients. In the first paper, an international panel presents new consensus recommendations for evaluation and treatment of ECD. In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Eosinophilic Disorders and Syndromes
Share to Histiocytic Disorders and Treatments
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32299103
DOI: 10.1182/blood.2019004478

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term follow-up of mTOR inhibition for Erdheim-Chester diseasePMID 32299103Read ↗

Erdheim-Chester disease.Semantic proximity Read ↗

Efficacy of MEK inhibitors in Erdheim-Chester disease: impact of MAPK pathway pathogenic variantsSemantic proximity Read ↗

Recent advances in therapeutic strategies of Erdheim-Chester disease.Semantic proximity Read ↗

Erdheim-Chester disease.Semantic proximity Read ↗

Recurrent RAS and PIK3CA mutations in Erdheim-Chester diseaseSemantic proximity Read ↗

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era.Semantic proximity Read ↗

Sustained, complete response to pexidartinib in a patient with CSF1R-mutated Erdheim-Chester disease.Semantic proximity Read ↗

Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case series.Semantic proximity Read ↗

Co-occurrence of Erdheim-Chester disease and clonally evolving acute myeloid leukemia with FLT3-ITD and PTPN11 mutations.Semantic proximity Read ↗

The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm.Semantic proximity Read ↗

Erdheim-Chester Disease with BRAF V600E Mutation and a Concomitant Myeloid Malignancy Sharing NRAS and IDH2 Mutations.Semantic proximity Read ↗

Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task ForceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.